17.59
17.59 (0%)
As of Feb 14, 2025
Nurix Therapeutics, Inc. [NRIX]
Source:
Company Overview
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases.
| Country | United States |
| Headquarters | san francisco, california |
| Phone Number | (415) 660-5320 |
| Industry | manufacturing |
| CEO | Arthur T. Sands |
| Website | www.nurixtx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $18.5 |
| Operating Profit | $-62.9 |
| Net Income | $-56.4 |
| Net Cash | $-34.1 |
Profit Ratios
| Gross Margin | $18.5 |
| Operating Margin | -340.7 |
| Profit as % of Revenues | -32.8% |
| Profit as % of Assets | -8.8% |
| Profit as % of Stockholder Equity | -11.7% |
Management Effectiveness
| Return on Equity | -11.7% |
| Return on Assets | -9.2% |
| Turnover Ratio | 2.9% |
| EBITA | $-62.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $615 |
| Total Liabilities | $134.1 |
| Operating Cash Flow | $-61.1 |
| Investing Cash Flow | $25.5 |
| Financing Cash Flow | $1.5 |
